Product Information
NEURONTIN 300 MG CAPSULE is a brand product labeled by Pfizer Inc., priced at $7.3865 per EA under NDC 00071080524. Its NADAC has been published 660 times since Nov 28, 2013.
FDA first approved this application on Dec 30, 1993. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the gabapentin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
Pfizer Inc.NDC
00071080524
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
1/1/2026
Active Ingredients
GABAPENTINApproval Type
New Drug (NDA)
FDA Application
NDA020235FDA Approved
12/30/1993
TE Code
AB
On Market Since
12/30/1993
Pharmacological Classes
Price Statistics
The NADAC for NEURONTIN 300 MG CAPSULE has been published 660 times since Nov 28, 2013, and over the history we have for it it has risen 209.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.3865 per EA |
|---|---|
| All-time high | $7.3865 (Aug 19, 2026) |
| All-time low | $2.3853 (Nov 28, 2013) |
| 52-week high | $7.3865 |
| 52-week low | $7.0348 |
| Median price | $5.6179 |
| Average price | $5.2783 |
| Largest weekly change | +13.0% (Jan 7, 2015) |
| Weeks tracked | 660 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of NEURONTIN 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for NEURONTIN 300 MG CAPSULE, manufactured by Pfizer Inc., is $7.3865 per EA (NDC 00071080524), effective Aug 19, 2026.
How has the price of NEURONTIN 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for NEURONTIN 300 MG CAPSULE has risen 209.7%. It has been tracked across 660 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for NEURONTIN 300 MG CAPSULE?
Since Nov 28, 2013, the NADAC for NEURONTIN 300 MG CAPSULE has ranged from a low of $2.3853 (Nov 28, 2013) to a high of $7.3865 (Aug 19, 2026), with a median of $5.6179 per EA.
Are there cheaper alternatives to NEURONTIN 300 MG CAPSULE?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GABAPENTIN 300 MG CAPSULE, is $0.0301 per EA — about 99% below NEURONTIN 300 MG CAPSULE.
Who manufactures NEURONTIN 300 MG CAPSULE?
NEURONTIN 300 MG CAPSULE (NDC 00071080524) is labeled by Pfizer Inc., and CMS classifies it as a brand product.